In this study, we revealed that METTL3 could mediate m6A modification on CDC25B mRNA and promote the malignant progression of HNSCC, proposing that METTL3 may be a potential predictive biomarker and therapeutic target for HNSCC. This evidence concerns the gene METTL3 and head and neck squamous cell carcinoma.